Results 191 to 200 of about 71,065 (294)

Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host‐Directed Strategies

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT The global burden of multidrug‐resistant tuberculosis (MDR‐TB) and the rising incidence of nontuberculous mycobacterial (NTM) infections highlight the urgent need for innovative therapeutic strategies. Current treatments are prolonged, toxic, and increasingly compromised by resistance and limited diagnostic capacity.
Tânia Silva   +23 more
wiley   +1 more source

Chemically Regulated STING-Activating Prodrugs of Deoxyribose Cyclic Dinucleotides Elicit Robust Immune Activation and Durable Antitumor Immunity. [PDF]

open access: yesAngew Chem Int Ed Engl
Xie Z   +14 more
europepmc   +1 more source

Boronic Acid Inhibitors of β‐Lactamases: A Promising Strategy Against Antimicrobial Resistance

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT The rise of antimicrobial resistance (AMR) poses a critical threat to global health, mostly due to the proliferation of β‐lactamases, a class of enzymes responsible for the inactivation of β‐lactam antibiotics. Among the most promising strategies to restore β‐lactam efficacy is the use of β‐lactamase inhibitors (BLIs), with boronic acid ...
Nicolò Santi   +4 more
wiley   +1 more source

Chondroitin Sulfate-Based Self-Assembling Nanoprodrug for Controlled Methotrexate Delivery in Cancer Therapy. [PDF]

open access: yesMolecules
Scorzafave L   +9 more
europepmc   +1 more source

Current status and future perspectives of platelet function‐guided precision antiplatelet therapy for patients with cerebral infarction

open access: yesNeuroprotection, EarlyView.
Antiplatelet agents target the cyclooxygenase‐1 (COX‐1)/thromboxane A2 (TXA2) and adenosine diphosphate (ADP)‐P2Y12 (cytochrome P450 2C19 [CYP2C19]‐metabolized) platelet activation pathways, resulting in either drug resistance or over‐inhibition. The individualized therapeutic window balances ischemic risk (triggered by high on‐treatment platelet ...
Guoliang Zhu   +7 more
wiley   +1 more source

Intranasal diamorphine population pharmacokinetics modeling and simulation in pediatric breakthrough pain

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 435-447, March 2025.
Abstract Intranasal diamorphine (IND), approved for managing breakthrough pain in the UK, has been identified as an acceptable alternative offering effective, expedient, and less traumatic analgesia for children. However, the current dose regimen in pediatric populations relies on clinical expertise while the pharmacokinetics properties are poorly ...
Lianjin Cai   +6 more
wiley   +1 more source

Plasma 3‐O‐Methyldopa Concentration Monitoring for Treatment Optimization in Foslevodopa/Foscarbidopa Infusion: Implications for Corrected Levodopa Availability: A Case Report

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Shohei Okusa   +8 more
wiley   +1 more source

Photo‐responsive carbon dots for pyroptosis‐mediated anti‐tumor application

open access: yesResponsive Materials, EarlyView.
Photo‐responsive CDs generate ROS to induce tumor cell pyroptosis, thereby stimulating antitumor immunity. Abstract Pyroptosis refers to a kind of lytic programmed cell death, characterized by the release of pro‐inflammatory cytokines during the process. Owing to its immune response stimulation ability, pyroptosis has garnered considerable attention in
Lingyun Li   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy